News from eisai europe limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

22 Apr, 2015, 00:01 BST Life Extending Metastatic Breast Cancer Treatment Halaven® (Eribulin) Launches in the United Arab Emirates

PRESS RELEASE FOR UAE AND UK MEDIA ONLY Halaven® (eribulin) launches today in the United Arab Emirates (UAE) for the treatment of women with locally...


27 Mar, 2015, 12:00 GMT Lenvima® (Lenvatinib) Receives Positive CHMP Opinion Following Significant Phase III Data in the Treatment of Advanced Thyroid Cancer Refractory to Radioactive Iodine

FOR EU MEDIA ONLY: NOT FOR SWISS AND AUSTRIAN MEDIA Eisai announces today that Lenvima® (lenvatinib) has received a positive opinion for the...


18 Mar, 2015, 00:01 GMT Advanced Breast Cancer Patient, Linda Johnson, Hands 14,300 Signatures to Parliament to Demand Immediate Halt to Cuts to Cancer Drugs Fund

PRESS RELEASE FOR UK MEDIA ONLY Linda Johnson, 57, who lives with advanced breast cancer and represents a group of women from Essex with the...


11 Mar, 2015, 00:01 GMT Eisai Confirms Life-extending Breast Cancer Treatment Halaven® (Eribulin) to Remain on Cancer Drugs Fund Pending Reconsideration

PRESS STATEMENT FOR UK MEDIA Cancer Programme of Care Board upholds the appeals against original decisions from the National Cancer Drugs Fund in...


26 Feb, 2015, 00:01 GMT Life-extending Advanced Breast Cancer Treatment Halaven® (Eribulin Mesylate) Launched in Kingdom of Saudi Arabia

- For EMEA media only: not for Swiss/U.S. Journalists Innovative breast cancer treatment Halaven® (eribulin mesylate) has recently been approved by...


25 Feb, 2015, 00:01 GMT Phase III Trial of Anticancer Agent Halaven® (eribulin) in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint

Eisai demonstrates commitment to rare cancers Eisai announces today that in the Phase III trial (Study 309) of Halaven® (eribulin) in patients with...


18 Feb, 2015, 00:01 GMT Eisai's Epilepsy Treatment Zonegran® (Zonisamide) Approved for Use in Children and Adolescents in France

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS On the 9 February, the Transparency Commission of the French National Authority for...


23 Jan, 2015, 00:01 GMT Considerable Additional Benefit of Eisai's Halaven® (eribulin) Confirmed by German Federal Joint Committee (G-BA)

German Federal Joint Committee decision supports the needs of women with advanced breast cancer in Germany The German Federal Joint Committee (G-BA)...


20 Jan, 2015, 00:01 GMT Exalief (Eslicarbazepine Acetate) Soon to be Available in Russia as a Once Daily Adjunctive Treatment of Partial Onset Seizures in Adults

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Novel, anti-epilepsy treatment Exalief® will soon be available in Russia. (Exalief is ...


08 Jan, 2015, 00:01 GMT Eisai is Appalled by Arbitrary Decision to Remove Life-Extending Breast Cancer Therapy Halaven® (Eribulin) From Cancer Drugs Fund

Decision means that thousands of women in England with secondary breast cancer will no longer have access to this treatment Eisai today announces its ...


18 Dec, 2014, 00:01 GMT Halaven® (Eribulin) Now Available in Russia for Advanced Breast Cancer After Only One Prior Chemotherapy, Which Provides New Therapy for Women Living With Aggressive Disease

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Eisai is pleased to announce that women with locally advanced or metastatic breast...


09 Dec, 2014, 14:01 GMT Halaven® (Eribulin) in Combination with Capecitabine Provides Clinical Benefit for Women with Metastatic Breast Cancer

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS A Second Phase II Study Presented at San Antonio Breast Cancer Symposium (SABCS) Show ...


08 Dec, 2014, 00:01 GMT New Data Show That 30% of People Were Free of Primary Generalised Tonic Clonic Seizures When Using Adjunctive Fycompa® (perampanel)

Press release for EU media only: not for Swiss/U.S. Journalists New data presented by Eisai at the American Epilepsy Society (AES) annual meeting...


01 Dec, 2014, 00:01 GMT Eisai to Present New Research on Halaven® (eribulin) at Annual San Antonio Breast Cancer Symposium

FOR EMEA MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Eisai presents new and important data for women with breast cancer Five abstracts to be presented ...


17 Nov, 2014, 00:01 GMT Eisai Receives Approval in Russia for its Antiepileptic Treatment Zonegran® (Zonisamide) for Use in Children and Adolescents

Zonegran® (zonisamide) receives approval in Russia for the treatment of partial epilepsy in children and adolescents. Zonisamide, a novel...


13 Nov, 2014, 00:01 GMT Pooled Analysis Results of Two Phase III Halaven® (eribulin) Trials Published in Breast Cancer Research and Treatment

Significant survival benefit observed in women with HER2 negative breast cancer The results from a pooled analysis of two Phase III Halaven®...


10 Nov, 2014, 00:01 GMT Eisai Neuroscience Business Officially Launched in Belgium and Luxembourg

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of one of...


10 Nov, 2014, 00:01 GMT Pooled Data from 17 Clinical Studies Support Safety of Adjunctive Zonegran® (Zonisamide) in Children Aged Six and Above

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS The safety profile of adjunctive Zonegran® (zonisamide) in paediatric patients with...


06 Nov, 2014, 14:50 GMT Eisai Speechless With G-BA Decision Which Ignores the Demand of Epilepsy Patients and Denies the Proven Additional Benefit of the First-in-class Treatment Fycompa® (Perampanel)

Eisai announces with utmost disappointment that the German Federal Joint Committee (G-BA) has decided that the additional benefit for new generation...


06 Nov, 2014, 13:00 GMT Eisai Continues Global Expansion with New Office in Melbourne, Australia

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS New Eisai office will support breast cancer treatment Halaven®(eribulin) and...


03 Nov, 2014, 19:41 GMT German Institute for Quality and Efficiency in Health Care (IQWIG) Confirms an Additional Benefit of Eisai's Halaven® (eribulin) for the Treatment of Advanced Breast Cancer

Reassessment acknowledges survival benefit for eribulin in difficult-to-treat HER2-negative breast cancer also in the expanded indication The German...


03 Nov, 2014, 00:01 GMT First-in-Class Epilepsy Treatment Fycompa® (Perampanel) Launches in Australia

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Fycompa® (perampanel), the first in an entirely new class of treatment for partial...


22 Oct, 2014, 00:01 BST Long-Term Safety and Efficacy of Once-Daily Zonegran® (zonisamide) Monotherapy Demonstrated in Extension of Pivotal Study

Zonegran® (zonisamide) continues to be well-tolerated and efficacious when used as long-term monotherapy for the treatment of partial onset seizures...


13 Oct, 2014, 00:01 BST Eisai Names Partner For Pan Middle East Distribution of First-in-class Epilepsy Treatment Fycompa® (perampanel)

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Fycompa® (perampanel), Eisai's first-in-class epilepsy treatment, will be made...


06 Oct, 2014, 00:01 BST French Transparency Commission Recognises Efficacy of Zonegran® (zonisamide) Monotherapy

Transparency advice for Zonegran® (zonisamide) monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults...